Patents by Inventor Kingston Mills
Kingston Mills has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230285531Abstract: The present invention relates to Toll-Like Receptor 2 (TLR2) agonists, in particular, to TLR2-activating lipoproteins, and more particularly to TLR2-activating lipopeptides derived from the bacteria Bordetella pertussis. The invention further extends to the use of said TLR2-activating lipoproteins as a therapeutic or as part of a vaccine composition in the treatment and prevention of infectious diseases, cancer or allergic diseases.Type: ApplicationFiled: October 4, 2022Publication date: September 14, 2023Applicant: The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the HolyInventors: Kingston MILLS, Aisling DUNNE
-
Patent number: 11497805Abstract: The present invention relates to Toll-Like Receptor 2 (TLR2) agonists, in particular, to TLR2-activating lipoproteins, and more particularly to TLR2-activating lipopeptides derived from the bacteria Bordetella pertussis. The invention further extends to the use of said TLR2-activating lipoproteins as a therapeutic or as part of a vaccine composition in the treatment and prevention of infectious diseases, cancer or allergic diseases.Type: GrantFiled: February 9, 2019Date of Patent: November 15, 2022Assignee: The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth, Near DublinInventors: Kingston Mills, Aisling Dunne
-
Publication number: 20190224296Abstract: The present invention relates to Toll-Like Receptor 2 (TLR2) agonists, in particular, to TLR2-activating lipoproteins, and more particularly to TLR2-activating lipopeptides derived from the bacteria Bordetella pertussis. The invention further extends to the use of said TLR2-activating lipoproteins as a therapeutic or as part of a vaccine composition in the treatment and prevention of infectious diseases, cancer or allergic diseases.Type: ApplicationFiled: February 9, 2019Publication date: July 25, 2019Applicant: The Provost, Fellows, Foundation Scholars & the Other Members of Board, Of the College of the HolyInventors: Kingston MILLS, Aisling Dunne
-
Publication number: 20170210778Abstract: A compound of formula (I) or a pharmaceutically acceptable derivative thereof, (formula 1) wherein R1, R2, R3, R4, R5, X, m and n are defined in the specification; a process for preparing such compounds; a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.Type: ApplicationFiled: July 15, 2015Publication date: July 27, 2017Inventors: Kingston Mills, Patrick Kelly, Jean-Gerard Tiraby, Thierry Lioux, Eric Perouzel
-
Publication number: 20170072044Abstract: The present invention relates to Toll-Like Receptor 2 (TLR2) agonists, in particular, to TLR2-activating lipoproteins, and more particularly to TLR2-activating lipopeptides derived from the bacteria Bordetella pertussis. The invention further extends to the use of said TLR2-activating lipoproteins as a therapeutic or as part of a vaccine composition in the treatment and prevention of infectious diseases, cancer or allergic diseases.Type: ApplicationFiled: March 18, 2015Publication date: March 16, 2017Applicant: The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the HolyInventors: Kingston MILLS, Aisling DUNNE
-
Patent number: 8105601Abstract: The present invention provides a composition for suppressing an inflammatory immune response comprising the excretory/secretory (ES) component of Fasciola hepatica or a fraction thereof. The composition has particular utility in the treatment or prophylaxis of T cell mediated inflammatory immune responses, and in particular autoimmune disease. The invention further extends to methods for modulating a T cell mediated immune response wherein a therapeutically effective amount of the excretory/secretory (ES) component from Fasciola hepatica is administered to a subject in need of such treatment in order to suppress the development of the response.Type: GrantFiled: December 5, 2006Date of Patent: January 31, 2012Assignee: The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near DublinInventors: Kingston Mills, Miriam Brady
-
Publication number: 20110294736Abstract: The present invention provides a method and composition for the treatment and prevention of an autoimmune disease such a multiple sclerosis which is mediated by autoreactive T cells. The administration of a NOD-1 agonist is shown to mediate an anti-inflammatory immune response. NOD-1 agonists suitable for use in the methods and compositions of the invention include diaminopimelic acid (DAP)-containing muropeptide compounds such as Tri-DAP and M-TriDAP.Type: ApplicationFiled: December 22, 2009Publication date: December 1, 2011Applicant: THE PROVOST, FELLOWS AND SCHOLARS OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLINInventors: Kingston Mills, Sarah Higgins
-
Publication number: 20100003287Abstract: The present invention provides methods for modulating an immune response by administering a composition comprising a Toll-like receptor agonist and an immune mediator which downregufates the expression of the anti-inflammatory cytokine IL-10 and upregulates the expression of the pro-inflammatory cytokine IL-12. The methods can be used to provide therapeutic treatment for cancerous conditions and infectious diseases.Type: ApplicationFiled: December 1, 2006Publication date: January 7, 2010Applicant: THE PROVOST, FELLOWS AND SCHOLARS OF THE COLL. OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETHInventors: Kingston Mills, Deirdre Toomey, Andrew Jarnicki
-
Publication number: 20090176696Abstract: The present invention provides compositions and methods for the suppression of Th2-mediated immune response. Tracheal cytotoxin is shown to mediate a selective suppression of T helper cell type 2 (Th2)-mediated immune responses. The methods and compositions of the invention are useful for the treatment of Th2-mediated diseases and conditions due to their utility in suppressing Th2-mediated immune responses. The invention further extends to methods for suppressing the production of cytokines, such as IL-4 and IL-5 which contribute to the development of Th2-mediated immune responses.Type: ApplicationFiled: April 18, 2007Publication date: July 9, 2009Applicant: The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen ElizabethInventors: Kingston Mills, Ed Lavelle, Sarah Higgins
-
Publication number: 20080260784Abstract: The present invention provides a composition for suppressing an inflammatory immune response comprising the excretory/secretory (ES) component of Fasciola hepatica or a fraction thereof. The composition has particular utility in the treatment or prophylaxis of T cell mediated inflammatory immune responses, and in particular autoimmune disease. The invention further extends to methods for modulating a T cell mediated immune response wherein a therapeutically effective amount of the excretory/secretory (ES) component from Fasciola hepatica is administered to a subject in need of such treatment in order to suppress the development of the response.Type: ApplicationFiled: December 5, 2006Publication date: October 23, 2008Inventors: Kingston Mills, Miriam Brady
-
Publication number: 20070190078Abstract: Filamentous haemagglutinin (FHA) or a derivative or mutant or fragment or variant or peptide thereof is useful in the prophylaxis and/or treatment of an immune-mediated disorder and/or an autoimmune disease. The FHA may include self or foreign antigens or peptides thereof.Type: ApplicationFiled: October 14, 2004Publication date: August 16, 2007Inventors: Kingston Mills, Peter Mcguirk, Brian Keogh
-
Publication number: 20060263379Abstract: This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection. Methods for using IL-12 as an adjuvant in combination with vaccines against Bordetella are also provided.Type: ApplicationFiled: July 27, 2006Publication date: November 23, 2006Applicant: National University of IrelandInventors: Kingston Mills, Bernard Mahon, Mark Ryan, Fiona Griffin
-
Publication number: 20060263380Abstract: This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection. Methods for using IL-12 as an adjuvant in combination with vaccines against Bordetella are also provided.Type: ApplicationFiled: July 27, 2006Publication date: November 23, 2006Applicant: National University of IrelandInventors: Kingston Mills, Bernard Mahon, Marks Ryan, Fiona Griffin
-
Publication number: 20060257419Abstract: This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection. Methods for using IL-12 as an adjuvant in combination with vaccines against Bordetella are also provided.Type: ApplicationFiled: July 27, 2006Publication date: November 16, 2006Applicant: National University of IrelandInventors: Kingston Mills, Bernard Mahon, Mark Ryan, Fiona Griffin
-
Publication number: 20060035335Abstract: A Hepatitis C virus (HCV) protein such as a non-structured protein 4 (NS4) or a non-structured protein 3 (NS3) or a derivative or fragment or variant or peptide thereof or product of cells activated by the agent is useful in the treatment and/or prophylaxis of an inflammatory and/or an immune-mediated disorder. The agent can also be used as a vaccine adjuvant.Type: ApplicationFiled: October 7, 2005Publication date: February 16, 2006Inventors: Kingston Mills, Miriam Brady
-
Publication number: 20050158276Abstract: This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection. Methods for using IL-12 as an adjuvant in combination with vaccines against Bordetella are also provided.Type: ApplicationFiled: March 4, 2005Publication date: July 21, 2005Applicant: National University of IrelandInventors: Kingston Mills, Bernard Mahon, Mark Rvan, Fiona Griffin